Illinois 100th Regular Session Status: Enacted Bipartisan · 3 D · 1 R cosponsors

SB 1585 — PHYSICIAN ASSISTANT-VARIOUS

Last action — Public Act . . . . . . . . . 100-0453

Track this bill free

No card. One bill, free forever — alerts when it moves.

  1. ✓
    Introduced
  2. ✓
    In Committee
  3. ✓
    Passed Senate
  4. ✓
    Passed House
  5. ✓
    To Executive
  6. 6
    Enacted

This bill has been enacted into law. Introduced February 09, 2017. Enacted.

Prognosis

Likely to advance 98% · high confidence

Where this bill stands today.

Odds of enactment

High

How often bills like it became law.

  • Enacted

    Current position in the legislative process.

  • 17 sponsors

    0 primary, 17 co-sponsors signed on.

  • Bipartisan support

    Sponsored across 2 parties (3 D · 1 R) — cross-party backing.

  • Cleared a recorded vote

    Passed 2 recorded votes so far.

Prognosis reads this bill's own signals — stage, sponsorship breadth, committee status, recorded votes and cross-state momentum. Odds come from a model trained on which bills have become law.

Summary

Amends the Regulatory Sunset Act. Extends the repeal date of the Physician Assistant Practice Act of 1987 from January 1, 2018 to January 1, 2028. Amends the Physician Assistant Practice Act of 1987. Reorganizes the Act by adding titles and renumbering provisions. Replaces references to "supervising physicians" with references to "collaborating physicians" throughout the Act. Replaces references to "supervision agreement" with references to "collaborative agreement" throughout the Act. Adds provisions concerning continuing education. In provisions concerning grounds for disciplinary action, provides that the Department of Financial and Professional Regulation may refuse to issue or renew a physician assistant license or discipline a licensee for willfully or negligently violating a patient's confidentiality, except as required by law, or failing to provide copies of medical records as required by law. Amends various Acts to conform references and terminology. Makes other changes. Effective immediately.

Bill Text

What changed in the latest version

89 added · 89 removed

Plain-language change summary

The latest version of Bill SB 1585 has made several updates, indicated by a transition from the "Engrossed" version to the "Enrolled" version. While the specific content of the changes is not detailed here, generally, this process involves finalizing language and provisions to ensure clarity and legal accuracy before the bill becomes law. These changes matter because they can affect how the bill is implemented and the impact it will have on the community or the intended audience.

→
Previous
Latest
SB1585 Engrossed LRB100 11277 SMS 21625 b AN ACT concerning regulation.
SB1585 Enrolled LRB100 11277 SMS 21625 b AN ACT concerning regulation.
SB1585 Engrossed - 2 - LRB100 11277 SMS 21625 b (Source:
SB1585 Enrolled - 2 - LRB100 11277 SMS 21625 b (Source:
A physician licensed to practice medicine in all its branches may enter into collaborative supervising physician agreements with no more than 5 full-time equivalent physician assistants, SB1585 Engrossed - 3 - LRB100 11277 SMS 21625 b except in a hospital, hospital affiliate, or ambulatory surgical treatment center as set forth by Section 7.7 of the Physician Assistant Practice Act of 1987 as set forth in subsection (a) of Section 7 of the Physician Assistant Practice Act of 1987.
A physician licensed to practice medicine in all its branches may enter into collaborative supervising physician agreements with no more than 5 full-time equivalent physician assistants, SB1585 Enrolled - 3 - LRB100 11277 SMS 21625 b except in a hospital, hospital affiliate, or ambulatory surgical treatment center as set forth by Section 7.7 of the Physician Assistant Practice Act of 1987 as set forth in subsection (a) of Section 7 of the Physician Assistant Practice Act of 1987.
With respect to labor and delivery, the collaborating physician must provide delivery services SB1585 Engrossed - 4 - LRB100 11277 SMS 21625 b in order to participate with a certified nurse midwife.
With respect to labor and delivery, the collaborating physician must provide delivery services SB1585 Enrolled - 4 - LRB100 11277 SMS 21625 b in order to participate with a certified nurse midwife.
Anesthesia services in a hospital shall be conducted in accordance with Section 10.7 of the Hospital Licensing Act and in an ambulatory surgical SB1585 Engrossed - 5 - LRB100 11277 SMS 21625 b treatment center in accordance with Section 6.5 of the Ambulatory Surgical Treatment Center Act.
Anesthesia services in a hospital shall be conducted in accordance with Section 10.7 of the Hospital Licensing Act and in an ambulatory surgical SB1585 Enrolled - 5 - LRB100 11277 SMS 21625 b treatment center in accordance with Section 6.5 of the Ambulatory Surgical Treatment Center Act.
(f) A collaborating physician may, but is not required to, delegate prescriptive authority to an advanced practice nurse as part of a written collaborative agreement, and the delegation of prescriptive authority shall conform to the SB1585 Engrossed - 6 - LRB100 11277 SMS 21625 b requirements of Section 65-40 of the Nurse Practice Act.
(f) A collaborating physician may, but is not required to, delegate prescriptive authority to an advanced practice nurse as part of a written collaborative agreement, and the delegation of prescriptive authority shall conform to the SB1585 Enrolled - 6 - LRB100 11277 SMS 21625 b requirements of Section 65-40 of the Nurse Practice Act.
The practice as a physician assistant in the State of Illinois is hereby declared to affect SB1585 Engrossed - 7 - LRB100 11277 SMS 21625 b the public health, safety and welfare and to be subject to regulation and control in the public interest.
The practice as a physician assistant in the State of Illinois is hereby declared to affect SB1585 Enrolled - 7 - LRB100 11277 SMS 21625 b the public health, safety and welfare and to be subject to regulation and control in the public interest.
The SB1585 Engrossed - 8 - LRB100 11277 SMS 21625 b Illinois Administrative Procedure Act is hereby expressly adopted and incorporated herein as if all of the provisions of that Act were included in this Act, except that the provision of subsection (d) of Section 10-65 of the Illinois Administrative Procedure Act that provides that at hearings the licensee has the right to show compliance with all lawful requirements for retention, continuation or renewal of the license is specifically excluded.
The SB1585 Enrolled - 8 - LRB100 11277 SMS 21625 b Illinois Administrative Procedure Act is hereby expressly adopted and incorporated herein as if all of the provisions of that Act were included in this Act, except that the provision of subsection (d) of Section 10-65 of the Illinois Administrative Procedure Act that provides that at hearings the licensee has the right to show compliance with all lawful requirements for retention, continuation or renewal of the license is specifically excluded.
"Physician assistant" means any person not holding an SB1585 Engrossed - 9 - LRB100 11277 SMS 21625 b active license or permit issued by the Department pursuant to the Medical Practice Act of 1987 who has been certified as a physician assistant by the National Commission on the Certification of Physician Assistants or equivalent successor agency and performs procedures in collaboration with under the supervision of a physician as defined in this Act.
"Physician assistant" means any person not holding an SB1585 Enrolled - 9 - LRB100 11277 SMS 21625 b active license or permit issued by the Department pursuant to the Medical Practice Act of 1987 who has been certified as a physician assistant by the National Commission on the Certification of Physician Assistants or equivalent successor agency and performs procedures in collaboration with under the supervision of a physician as defined in this Act.
The delegated tasks or duties shall be specific to the practice setting and shall be implemented and reviewed SB1585 Engrossed - 10 - LRB100 11277 SMS 21625 b under a written collaborative supervision agreement established by the physician or physician/physician assistant team.
The delegated tasks or duties shall be specific to the practice setting and shall be implemented and reviewed SB1585 Enrolled - 10 - LRB100 11277 SMS 21625 b under a written collaborative supervision agreement established by the physician or physician/physician assistant team.
Collaboration with the physician assistant shall not be construed to necessarily require the personal presence of the collaborating physician at all times at the place where services are rendered, as long as there is communication available for consultation by radio, telephone, SB1585 Engrossed - 11 - LRB100 11277 SMS 21625 b telecommunications, or electronic communications.
Collaboration with the physician assistant shall not be construed to necessarily require the personal presence of the collaborating physician at all times at the place where services are rendered, as long as there is communication available for consultation by radio, telephone, SB1585 Enrolled - 11 - LRB100 11277 SMS 21625 b telecommunications, or electronic communications.
Such tasks and procedures shall be delegated in accordance with SB1585 Engrossed - 12 - LRB100 11277 SMS 21625 b a written collaborative agreement.
Such tasks and procedures shall be delegated in accordance with SB1585 Enrolled - 12 - LRB100 11277 SMS 21625 b a written collaborative agreement.
"Address of record" means the designated address recorded by the Department in the applicant's or licensee's application file or license file maintained by the Department's SB1585 Engrossed - 13 - LRB100 11277 SMS 21625 b licensure maintenance unit.
"Address of record" means the designated address recorded by the Department in the applicant's or licensee's application file or license file maintained by the Department's SB1585 Enrolled - 13 - LRB100 11277 SMS 21625 b licensure maintenance unit.
1-1-16.) (225 ILCS 95/4.5 new) SB1585 Engrossed - 14 - LRB100 11277 SMS 21625 b Sec.
1-1-16.) (225 ILCS 95/4.5 new) SB1585 Enrolled - 14 - LRB100 11277 SMS 21625 b Sec.
The practice, services, or activities of persons SB1585 Engrossed - 15 - LRB100 11277 SMS 21625 b practicing the specified occupations set forth in subsection (a) of, and pursuant to a licensing exemption granted in subsection (b) or (d) of, Section 2105-350 of the Department of Professional Regulation Law of the Civil Administrative Code of Illinois, but only for so long as the 2016 Olympic and Paralympic Games Professional Licensure Exemption Law is operable.
The practice, services, or activities of persons SB1585 Enrolled - 15 - LRB100 11277 SMS 21625 b practicing the specified occupations set forth in subsection (a) of, and pursuant to a licensing exemption granted in subsection (b) or (d) of, Section 2105-350 of the Department of Professional Regulation Law of the Civil Administrative Code of Illinois, but only for so long as the 2016 Olympic and Paralympic Games Professional Licensure Exemption Law is operable.
SB1585 Engrossed - 16 - LRB100 11277 SMS 21625 b (3) publication of the person's collaborating physician's name, title, and areas of specialization;
SB1585 Enrolled - 16 - LRB100 11277 SMS 21625 b (3) publication of the person's collaborating physician's name, title, and areas of specialization;
(e) It is unlawful and punishable under the penalty provisions of this Act for a person licensed under this Act to knowingly advertise that the licensee will accept as payment SB1585 Engrossed - 17 - LRB100 11277 SMS 21625 b for services rendered by assignment from any third-party payor the amount the third-party payor covers as payment in full if the effect is to give the impression of eliminating the need of payment by the patient of any required deductible or copayment applicable in the patient's health benefit plan.
(e) It is unlawful and punishable under the penalty provisions of this Act for a person licensed under this Act to knowingly advertise that the licensee will accept as payment SB1585 Enrolled - 17 - LRB100 11277 SMS 21625 b for services rendered by assignment from any third-party payor the amount the third-party payor covers as payment in full if the effect is to give the impression of eliminating the need of payment by the patient of any required deductible or copayment applicable in the patient's health benefit plan.
advertising SB1585 Engrossed - 18 - LRB100 11277 SMS 21625 b billing.
advertising SB1585 Enrolled - 18 - LRB100 11277 SMS 21625 b billing.
(d) The collaborating supervising physician shall file with the Department notice of employment, discharge, or SB1585 Engrossed - 19 - LRB100 11277 SMS 21625 b collaboration with supervisory control of a physician assistant at the time of employment, discharge, or assumption of collaboration with supervisory control of a physician assistant.
(d) The collaborating supervising physician shall file with the Department notice of employment, discharge, or SB1585 Enrolled - 19 - LRB100 11277 SMS 21625 b collaboration with supervisory control of a physician assistant at the time of employment, discharge, or assumption of collaboration with supervisory control of a physician assistant.
A supervising physician may SB1585 Engrossed - 20 - LRB100 11277 SMS 21625 b supervise a maximum of 5 full-time equivalent physician assistants;
A supervising physician may SB1585 Enrolled - 20 - LRB100 11277 SMS 21625 b supervise a maximum of 5 full-time equivalent physician assistants;
Nothing in this Act shall be construed to prohibit the employment of physician assistants by a hospital, nursing home or other health care facility where such physician assistants function under a collaborating the supervision of a supervising SB1585 Engrossed - 21 - LRB100 11277 SMS 21625 b physician.
Nothing in this Act shall be construed to prohibit the employment of physician assistants by a hospital, nursing home or other health care facility where such physician assistants function under a collaborating the supervision of a supervising SB1585 Enrolled - 21 - LRB100 11277 SMS 21625 b physician.
Any physician who collaborates with supervises a physician assistant providing medical care in response to such an emergency or state or local disaster shall not be required to meet the requirements set forth in this Section for a SB1585 Engrossed - 22 - LRB100 11277 SMS 21625 b collaborating supervising physician.
Any physician who collaborates with supervises a physician assistant providing medical care in response to such an emergency or state or local disaster shall not be required to meet the requirements set forth in this Section for a SB1585 Enrolled - 22 - LRB100 11277 SMS 21625 b collaborating supervising physician.
The written collaborative supervision agreement need not describe the exact steps that a physician assistant must take with respect to each specific condition, disease, or symptom but SB1585 Engrossed - 23 - LRB100 11277 SMS 21625 b must specify which authorized procedures require the presence of the collaborating supervising physician as the procedures are being performed.
The written collaborative supervision agreement need not describe the exact steps that a physician assistant must take with respect to each specific condition, disease, or symptom but SB1585 Enrolled - 23 - LRB100 11277 SMS 21625 b must specify which authorized procedures require the presence of the collaborating supervising physician as the procedures are being performed.
(A) Participates in the joint formulation and joint approval of orders or guidelines with the physician assistant and he or she periodically reviews such orders and the services provided patients under SB1585 Engrossed - 24 - LRB100 11277 SMS 21625 b such orders in accordance with accepted standards of medical practice and physician assistant practice.
(A) Participates in the joint formulation and joint approval of orders or guidelines with the physician assistant and he or she periodically reviews such orders and the services provided patients under SB1585 Enrolled - 24 - LRB100 11277 SMS 21625 b such orders in accordance with accepted standards of medical practice and physician assistant practice.
The collaborating supervising physician must have a valid, current Illinois controlled substance license and SB1585 Engrossed - 25 - LRB100 11277 SMS 21625 b federal registration with the Drug Enforcement Agency to delegate the authority to prescribe controlled substances.
The collaborating supervising physician must have a valid, current Illinois controlled substance license and SB1585 Enrolled - 25 - LRB100 11277 SMS 21625 b federal registration with the Drug Enforcement Agency to delegate the authority to prescribe controlled substances.
(3) In addition to the requirements of this subsection (b) of this Section, a collaborating supervising physician may, but is not required to, delegate authority to a physician assistant to prescribe Schedule II controlled SB1585 Engrossed - 26 - LRB100 11277 SMS 21625 b substances, if all of the following conditions apply:
(3) In addition to the requirements of this subsection (b) of this Section, a collaborating supervising physician may, but is not required to, delegate authority to a physician assistant to prescribe Schedule II controlled SB1585 Enrolled - 26 - LRB100 11277 SMS 21625 b substances, if all of the following conditions apply:
(c) Nothing in this Act shall be construed to limit the delegation of tasks or duties by a physician to a licensed SB1585 Engrossed - 27 - LRB100 11277 SMS 21625 b practical nurse, a registered professional nurse, or other persons.
(c) Nothing in this Act shall be construed to limit the delegation of tasks or duties by a physician to a licensed SB1585 Enrolled - 27 - LRB100 11277 SMS 21625 b practical nurse, a registered professional nurse, or other persons.
Physician assistants in hospitals, hospital SB1585 Engrossed - 28 - LRB100 11277 SMS 21625 b affiliates, or ambulatory surgical treatment centers.
Physician assistants in hospitals, hospital SB1585 Enrolled - 28 - LRB100 11277 SMS 21625 b affiliates, or ambulatory surgical treatment centers.
SB1585 Engrossed - 29 - LRB100 11277 SMS 21625 b (a-5) Physician assistants practicing in a hospital affiliate may be, but are not required to be, granted authority to prescribe Schedule II through V controlled substances when such authority is recommended by the appropriate physician committee of the hospital affiliate and granted by the hospital affiliate.
SB1585 Enrolled - 29 - LRB100 11277 SMS 21625 b (a-5) Physician assistants practicing in a hospital affiliate may be, but are not required to be, granted authority to prescribe Schedule II through V controlled substances when such authority is recommended by the appropriate physician committee of the hospital affiliate and granted by the hospital affiliate.
Upon receipt of this notice of grant of authority to prescribe any Schedule II through V controlled substances, the licensed physician assistant may register for a mid-level practitioner controlled substance license under Section 303.05 of the SB1585 Engrossed - 30 - LRB100 11277 SMS 21625 b Illinois Controlled Substances Act.
Upon receipt of this notice of grant of authority to prescribe any Schedule II through V controlled substances, the licensed physician assistant may register for a mid-level practitioner controlled substance license under Section 303.05 of the SB1585 Enrolled - 30 - LRB100 11277 SMS 21625 b Illinois Controlled Substances Act.
and (5) the physician assistant must meet the education SB1585 Engrossed - 31 - LRB100 11277 SMS 21625 b requirements of Section 303.05 of the Illinois Controlled Substances Act.
and (5) the physician assistant must meet the education SB1585 Enrolled - 31 - LRB100 11277 SMS 21625 b requirements of Section 303.05 of the Illinois Controlled Substances Act.
An application shall include evidence of passage of the examination of the National Commission on the Certification of Physician Assistants, or its successor agency, and proof that SB1585 Engrossed - 32 - LRB100 11277 SMS 21625 b the applicant holds a valid certificate issued by that Commission.
An application shall include evidence of passage of the examination of the National Commission on the Certification of Physician Assistants, or its successor agency, and proof that SB1585 Enrolled - 32 - LRB100 11277 SMS 21625 b the applicant holds a valid certificate issued by that Commission.
(a) Any person who practices, offers to practice, attempts to practice, or holds oneself out to practice as a physician's SB1585 Engrossed - 33 - LRB100 11277 SMS 21625 b assistant without being licensed under this Act shall, in addition to any other penalty provided by law, pay a civil penalty to the Department in an amount not to exceed $10,000 for each offense as determined by the Department.
(a) Any person who practices, offers to practice, attempts to practice, or holds oneself out to practice as a physician's SB1585 Enrolled - 33 - LRB100 11277 SMS 21625 b assistant without being licensed under this Act shall, in addition to any other penalty provided by law, pay a civil penalty to the Department in an amount not to exceed $10,000 for each offense as determined by the Department.
The Department shall SB1585 Engrossed - 34 - LRB100 11277 SMS 21625 b adopt rules for continuing education for persons licensed under this Act that require 50 hours of continuing education per 2-year license renewal cycle.
The Department shall SB1585 Enrolled - 34 - LRB100 11277 SMS 21625 b adopt rules for continuing education for persons licensed under this Act that require 50 hours of continuing education per 2-year license renewal cycle.
has Has applied in writing or electronically in form and substance satisfactory to the Department and has not violated any of the provisions of Section 21 of this Act or SB1585 Engrossed - 35 - LRB100 11277 SMS 21625 b the rules adopted under this Act promulgated hereunder.
has Has applied in writing or electronically in form and substance satisfactory to the Department and has not violated any of the provisions of Section 21 of this Act or SB1585 Enrolled - 35 - LRB100 11277 SMS 21625 b the rules adopted under this Act promulgated hereunder.
Promulgate rules approved by the Board SB1585 Engrossed - 36 - LRB100 11277 SMS 21625 b setting forth uniform and reasonable standards of instruction to be met prior to approval of such course of institution for physician assistants;
Promulgate rules approved by the Board SB1585 Enrolled - 36 - LRB100 11277 SMS 21625 b setting forth uniform and reasonable standards of instruction to be met prior to approval of such course of institution for physician assistants;
SB1585 Engrossed - 37 - LRB100 11277 SMS 21625 b (c) All moneys collected under this Act by the Department shall be deposited in the Illinois State Medical Disciplinary Fund in the State Treasury and used (1) in the exercise of its powers and performance of its duties under this Act, as such use is made by the Department;
SB1585 Enrolled - 37 - LRB100 11277 SMS 21625 b (c) All moneys collected under this Act by the Department shall be deposited in the Illinois State Medical Disciplinary Fund in the State Treasury and used (1) in the exercise of its powers and performance of its duties under this Act, as such use is made by the Department;
Any physician assistant who has permitted his or her license to expire or who has had his or her license on inactive SB1585 Engrossed - 38 - LRB100 11277 SMS 21625 b status may have the license restored by making application to the Department and filing proof acceptable to the Department of his or her fitness to have the license restored, and by paying the required fees.
Any physician assistant who has permitted his or her license to expire or who has had his or her license on inactive SB1585 Enrolled - 38 - LRB100 11277 SMS 21625 b status may have the license restored by making application to the Department and filing proof acceptable to the Department of his or her fitness to have the license restored, and by paying the required fees.
4621) SB1585 Engrossed - 39 - LRB100 11277 SMS 21625 b (Section scheduled to be repealed on January 1, 2018) Sec.
4621) SB1585 Enrolled - 39 - LRB100 11277 SMS 21625 b (Section scheduled to be repealed on January 1, 2018) Sec.
Conviction of or entry of a plea of guilty or nolo contendere to any crime that is a felony under the laws of the United States or any state or territory thereof or that is a misdemeanor of which an essential element is dishonesty or that is directly related to the practice of SB1585 Engrossed - 40 - LRB100 11277 SMS 21625 b the profession.
Conviction of or entry of a plea of guilty or nolo contendere to any crime that is a felony under the laws of the United States or any state or territory thereof or that is a misdemeanor of which an essential element is dishonesty or that is directly related to the practice of SB1585 Enrolled - 40 - LRB100 11277 SMS 21625 b the profession.
Show all 88 changed rows (48 more)
Previous
Latest
Nothing in this paragraph (11) affects any bona fide independent contractor or employment arrangements, which may include provisions for compensation, health SB1585 Engrossed - 41 - LRB100 11277 SMS 21625 b insurance, pension, or other employment benefits, with persons or entities authorized under this Act for the provision of services within the scope of the licensee's practice under this Act.
Nothing in this paragraph (11) affects any bona fide independent contractor or employment arrangements, which may include provisions for compensation, health SB1585 Enrolled - 41 - LRB100 11277 SMS 21625 b insurance, pension, or other employment benefits, with persons or entities authorized under this Act for the provision of services within the scope of the licensee's practice under this Act.
SB1585 Engrossed - 42 - LRB100 11277 SMS 21625 b (18) (Blank).
SB1585 Enrolled - 42 - LRB100 11277 SMS 21625 b (18) (Blank).
(27) Prescribing, selling, administering, distributing, giving, or self-administering a drug classified as a controlled substance (designated product) or narcotic for other than medically-accepted therapeutic SB1585 Engrossed - 43 - LRB100 11277 SMS 21625 b purposes.
(27) Prescribing, selling, administering, distributing, giving, or self-administering a drug classified as a controlled substance (designated product) or narcotic for other than medically-accepted therapeutic SB1585 Enrolled - 43 - LRB100 11277 SMS 21625 b purposes.
(36) Willfully failing to report an instance of SB1585 Engrossed - 44 - LRB100 11277 SMS 21625 b suspected abuse, neglect, financial exploitation, or self-neglect of an eligible adult as defined in and required by the Adult Protective Services Act.
(36) Willfully failing to report an instance of SB1585 Enrolled - 44 - LRB100 11277 SMS 21625 b suspected abuse, neglect, financial exploitation, or self-neglect of an eligible adult as defined in and required by the Adult Protective Services Act.
SB1585 Engrossed - 45 - LRB100 11277 SMS 21625 b (c) The determination by a circuit court that a licensee is subject to involuntary admission or judicial admission as provided in the Mental Health and Developmental Disabilities Code operates as an automatic suspension.
SB1585 Enrolled - 45 - LRB100 11277 SMS 21625 b (c) The determination by a circuit court that a licensee is subject to involuntary admission or judicial admission as provided in the Mental Health and Developmental Disabilities Code operates as an automatic suspension.
The multidisciplinary team shall be led by a physician licensed to practice medicine in all of its branches and may consist of one or more or a combination of physicians licensed to practice medicine in all of its branches, licensed clinical psychologists, licensed clinical social workers, licensed SB1585 Engrossed - 46 - LRB100 11277 SMS 21625 b clinical professional counselors, and other professional and administrative staff.
The multidisciplinary team shall be led by a physician licensed to practice medicine in all of its branches and may consist of one or more or a combination of physicians licensed to practice medicine in all of its branches, licensed clinical psychologists, licensed clinical social workers, licensed SB1585 Enrolled - 46 - LRB100 11277 SMS 21625 b clinical professional counselors, and other professional and administrative staff.
No authorization is necessary from the licensee or applicant ordered to undergo an examination for the examining physician or any member of the multidisciplinary team to provide information, reports, records, or other documents or to provide any testimony regarding the examination and SB1585 Engrossed - 47 - LRB100 11277 SMS 21625 b evaluation.
No authorization is necessary from the licensee or applicant ordered to undergo an examination for the examining physician or any member of the multidisciplinary team to provide information, reports, records, or other documents or to provide any testimony regarding the examination and SB1585 Enrolled - 47 - LRB100 11277 SMS 21625 b evaluation.
An individual whose license was granted, continued, reinstated, renewed, disciplined, or supervised subject to such terms, conditions, or restrictions, and who fails to comply with such terms, conditions, or restrictions, shall be referred to the Secretary SB1585 Engrossed - 48 - LRB100 11277 SMS 21625 b for a determination as to whether the individual shall have his or her license suspended immediately, pending a hearing by the Department.
An individual whose license was granted, continued, reinstated, renewed, disciplined, or supervised subject to such terms, conditions, or restrictions, and who fails to comply with such terms, conditions, or restrictions, shall be referred to the Secretary SB1585 Enrolled - 48 - LRB100 11277 SMS 21625 b for a determination as to whether the individual shall have his or her license suspended immediately, pending a hearing by the Department.
(f) Members of the Board and the Disciplinary Board shall SB1585 Engrossed - 49 - LRB100 11277 SMS 21625 b be indemnified by the State for any actions occurring within the scope of services on the Disciplinary Board or Board, done in good faith and not willful and wanton in nature.
(f) Members of the Board and the Disciplinary Board shall SB1585 Enrolled - 49 - LRB100 11277 SMS 21625 b be indemnified by the State for any actions occurring within the scope of services on the Disciplinary Board or Board, done in good faith and not willful and wanton in nature.
4622.2) (Section scheduled to be repealed on January 1, 2018) SB1585 Engrossed - 50 - LRB100 11277 SMS 21625 b Sec.
4622.2) (Section scheduled to be repealed on January 1, 2018) SB1585 Enrolled - 50 - LRB100 11277 SMS 21625 b Sec.
The SB1585 Engrossed - 51 - LRB100 11277 SMS 21625 b Department may continue such hearing from time to time.
The SB1585 Enrolled - 51 - LRB100 11277 SMS 21625 b Department may continue such hearing from time to time.
If the Secretary disagrees in any regard SB1585 Engrossed - 52 - LRB100 11277 SMS 21625 b with the report of the Disciplinary Board, the Secretary may issue an order in contravention thereof.
If the Secretary disagrees in any regard SB1585 Enrolled - 52 - LRB100 11277 SMS 21625 b with the report of the Disciplinary Board, the Secretary may issue an order in contravention thereof.
The Disciplinary Board shall have 60 days from receipt of the report to review the report of the hearing officer and present their findings of fact, conclusions of law, and recommendations SB1585 Engrossed - 53 - LRB100 11277 SMS 21625 b to the Secretary.
The Disciplinary Board shall have 60 days from receipt of the report to review the report of the hearing officer and present their findings of fact, conclusions of law, and recommendations SB1585 Enrolled - 53 - LRB100 11277 SMS 21625 b to the Secretary.
Notwithstanding any other provision of this Section, if the Secretary, upon review, determines that substantial justice has not been done in the revocation, suspension, or refusal to issue or renew a license or other disciplinary action taken as the result of the SB1585 Engrossed - 54 - LRB100 11277 SMS 21625 b entry of the hearing officer's report, the Secretary may order a rehearing by the same or other examiners.
Notwithstanding any other provision of this Section, if the Secretary, upon review, determines that substantial justice has not been done in the revocation, suspension, or refusal to issue or renew a license or other disciplinary action taken as the result of the SB1585 Enrolled - 54 - LRB100 11277 SMS 21625 b entry of the hearing officer's report, the Secretary may order a rehearing by the same or other examiners.
A license that has been suspended or revoked shall be considered nonrenewed for purposes of restoration and a person restoring his or her license from suspension or revocation must SB1585 Engrossed - 55 - LRB100 11277 SMS 21625 b comply with the requirements for restoration of a nonrenewed license as set forth in Section 16 of this Act and any related rules adopted.
A license that has been suspended or revoked shall be considered nonrenewed for purposes of restoration and a person restoring his or her license from suspension or revocation must SB1585 Enrolled - 55 - LRB100 11277 SMS 21625 b comply with the requirements for restoration of a nonrenewed license as set forth in Section 16 of this Act and any related rules adopted.
Failure on the part of the plaintiff to file a receipt in court is grounds for dismissal SB1585 Engrossed - 56 - LRB100 11277 SMS 21625 b of the action.
Failure on the part of the plaintiff to file a receipt in court is grounds for dismissal SB1585 Enrolled - 56 - LRB100 11277 SMS 21625 b of the action.
A formal complaint filed against a licensee by the Department or any order issued by the SB1585 Engrossed - 57 - LRB100 11277 SMS 21625 b Department against a licensee or applicant shall be a public record, except as otherwise prohibited by law.
A formal complaint filed against a licensee by the Department or any order issued by the SB1585 Enrolled - 57 - LRB100 11277 SMS 21625 b Department against a licensee or applicant shall be a public record, except as otherwise prohibited by law.
In supplying medical assistance, the Illinois Department may provide for the legally authorized services of (i) persons licensed under the Medical Practice Act of 1987, as amended, except as hereafter in this Section stated, whether under a general or limited license, (ii) persons licensed under the Nurse Practice Act as advanced practice nurses, regardless of whether or not the persons have SB1585 Engrossed - 58 - LRB100 11277 SMS 21625 b written collaborative agreements, (iii) persons licensed or registered under other laws of this State to provide dental, medical, pharmaceutical, optometric, podiatric, or nursing services, or other remedial care recognized under State law, and (iv) persons licensed under other laws of this State as a clinical social worker, and (v) persons licensed under other laws of this State as physician assistants.
In supplying medical assistance, the Illinois Department may provide for the legally authorized services of (i) persons licensed under the Medical Practice Act of 1987, as amended, except as hereafter in this Section stated, whether under a general or limited license, (ii) persons licensed under the Nurse Practice Act as advanced practice nurses, regardless of whether or not the persons have SB1585 Enrolled - 58 - LRB100 11277 SMS 21625 b written collaborative agreements, (iii) persons licensed or registered under other laws of this State to provide dental, medical, pharmaceutical, optometric, podiatric, or nursing services, or other remedial care recognized under State law, and (iv) persons licensed under other laws of this State as a clinical social worker, and (v) persons licensed under other laws of this State as physician assistants.
As used in this Act, unless the SB1585 Engrossed - 59 - LRB100 11277 SMS 21625 b context otherwise requires:
As used in this Act, unless the SB1585 Enrolled - 59 - LRB100 11277 SMS 21625 b context otherwise requires:
(c-1) "Anabolic Steroids" means any drug or hormonal substance, chemically and pharmacologically related to testosterone (other than estrogens, progestins, SB1585 Engrossed - 60 - LRB100 11277 SMS 21625 b corticosteroids, and dehydroepiandrosterone), and includes:
(c-1) "Anabolic Steroids" means any drug or hormonal substance, chemically and pharmacologically related to testosterone (other than estrogens, progestins, SB1585 Enrolled - 60 - LRB100 11277 SMS 21625 b corticosteroids, and dehydroepiandrosterone), and includes:
(i) 3[beta],17-dihydroxy-5a-androstane, (ii) 3[alpha],17[beta]-dihydroxy-5a-androstane, (iii) 5[alpha]-androstan-3,17-dione, (iv) 1-androstenediol (3[beta], 17[beta]-dihydroxy-5[alpha]-androst-1-ene), (v) 1-androstenediol (3[alpha], 17[beta]-dihydroxy-5[alpha]-androst-1-ene), (vi) 4-androstenediol (3[beta],17[beta]-dihydroxy-androst-4-ene), (vii) 5-androstenediol (3[beta],17[beta]-dihydroxy-androst-5-ene), (viii) 1-androstenedione ([5alpha]-androst-1-en-3,17-dione), (ix) 4-androstenedione (androst-4-en-3,17-dione), (x) 5-androstenedione (androst-5-en-3,17-dione), (xi) bolasterone (7[alpha],17a-dimethyl-17[beta]- hydroxyandrost-4-en-3-one), (xii) boldenone (17[beta]-hydroxyandrost- 1,4,-diene-3-one), (xiii) boldione (androsta-1,4- diene-3,17-dione), (xiv) calusterone (7[beta],17[alpha]-dimethyl-17 [beta]-hydroxyandrost-4-en-3-one), SB1585 Engrossed - 61 - LRB100 11277 SMS 21625 b (xv) clostebol (4-chloro-17[beta]- hydroxyandrost-4-en-3-one), (xvi) dehydrochloromethyltestosterone (4-chloro- 17[beta]-hydroxy-17[alpha]-methyl- androst-1,4-dien-3-one), (xvii) desoxymethyltestosterone (17[alpha]-methyl-5[alpha] -androst-2-en-17[beta]-ol)(a.k.a., madol), (xviii) [delta]1-dihydrotestosterone (a.k.a.
(i) 3[beta],17-dihydroxy-5a-androstane, (ii) 3[alpha],17[beta]-dihydroxy-5a-androstane, (iii) 5[alpha]-androstan-3,17-dione, (iv) 1-androstenediol (3[beta], 17[beta]-dihydroxy-5[alpha]-androst-1-ene), (v) 1-androstenediol (3[alpha], 17[beta]-dihydroxy-5[alpha]-androst-1-ene), (vi) 4-androstenediol (3[beta],17[beta]-dihydroxy-androst-4-ene), (vii) 5-androstenediol (3[beta],17[beta]-dihydroxy-androst-5-ene), (viii) 1-androstenedione ([5alpha]-androst-1-en-3,17-dione), (ix) 4-androstenedione (androst-4-en-3,17-dione), (x) 5-androstenedione (androst-5-en-3,17-dione), (xi) bolasterone (7[alpha],17a-dimethyl-17[beta]- hydroxyandrost-4-en-3-one), (xii) boldenone (17[beta]-hydroxyandrost- 1,4,-diene-3-one), (xiii) boldione (androsta-1,4- diene-3,17-dione), (xiv) calusterone (7[beta],17[alpha]-dimethyl-17 [beta]-hydroxyandrost-4-en-3-one), SB1585 Enrolled - 61 - LRB100 11277 SMS 21625 b (xv) clostebol (4-chloro-17[beta]- hydroxyandrost-4-en-3-one), (xvi) dehydrochloromethyltestosterone (4-chloro- 17[beta]-hydroxy-17[alpha]-methyl- androst-1,4-dien-3-one), (xvii) desoxymethyltestosterone (17[alpha]-methyl-5[alpha] -androst-2-en-17[beta]-ol)(a.k.a., madol), (xviii) [delta]1-dihydrotestosterone (a.k.a.
'1-testosterone') (17[beta]-hydroxy- 5[alpha]-androst-1-en-3-one), (xix) 4-dihydrotestosterone (17[beta]-hydroxy- androstan-3-one), (xx) drostanolone (17[beta]-hydroxy-2[alpha]-methyl- 5[alpha]-androstan-3-one), (xxi) ethylestrenol (17[alpha]-ethyl-17[beta]- hydroxyestr-4-ene), (xxii) fluoxymesterone (9-fluoro-17[alpha]-methyl- 1[beta],17[beta]-dihydroxyandrost-4-en-3-one), (xxiii) formebolone (2-formyl-17[alpha]-methyl-11[alpha], 17[beta]-dihydroxyandrost-1,4-dien-3-one), (xxiv) furazabol (17[alpha]-methyl-17[beta]- hydroxyandrostano[2,3-c]-furazan), (xxv) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one) (xxvi) 4-hydroxytestosterone (4,17[beta]-dihydroxy- androst-4-en-3-one), SB1585 Engrossed - 62 - LRB100 11277 SMS 21625 b (xxvii) 4-hydroxy-19-nortestosterone (4,17[beta]- dihydroxy-estr-4-en-3-one), (xxviii) mestanolone (17[alpha]-methyl-17[beta]- hydroxy-5-androstan-3-one), (xxix) mesterolone (1amethyl-17[beta]-hydroxy- [5a]-androstan-3-one), (xxx) methandienone (17[alpha]-methyl-17[beta]- hydroxyandrost-1,4-dien-3-one), (xxxi) methandriol (17[alpha]-methyl-3[beta],17[beta]- dihydroxyandrost-5-ene), (xxxii) methenolone (1-methyl-17[beta]-hydroxy- 5[alpha]-androst-1-en-3-one), (xxxiii) 17[alpha]-methyl-3[beta], 17[beta]- dihydroxy-5a-androstane), (xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy -5a-androstane), (xxxv) 17[alpha]-methyl-3[beta],17[beta]- dihydroxyandrost-4-ene), (xxxvi) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]- methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one), (xxxvii) methyldienolone (17[alpha]-methyl-17[beta]- hydroxyestra-4,9(10)-dien-3-one), (xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]- hydroxyestra-4,9-11-trien-3-one), (xxxix) methyltestosterone (17[alpha]-methyl-17[beta]- hydroxyandrost-4-en-3-one), SB1585 Engrossed - 63 - LRB100 11277 SMS 21625 b (xl) mibolerone (7[alpha],17a-dimethyl-17[beta]- hydroxyestr-4-en-3-one), (xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone (17b[beta]-hydroxy-17[alpha]-methyl-5[alpha]- androst-1-en-3-one)(a.k.a.
'1-testosterone') (17[beta]-hydroxy- 5[alpha]-androst-1-en-3-one), (xix) 4-dihydrotestosterone (17[beta]-hydroxy- androstan-3-one), (xx) drostanolone (17[beta]-hydroxy-2[alpha]-methyl- 5[alpha]-androstan-3-one), (xxi) ethylestrenol (17[alpha]-ethyl-17[beta]- hydroxyestr-4-ene), (xxii) fluoxymesterone (9-fluoro-17[alpha]-methyl- 1[beta],17[beta]-dihydroxyandrost-4-en-3-one), (xxiii) formebolone (2-formyl-17[alpha]-methyl-11[alpha], 17[beta]-dihydroxyandrost-1,4-dien-3-one), (xxiv) furazabol (17[alpha]-methyl-17[beta]- hydroxyandrostano[2,3-c]-furazan), (xxv) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one) (xxvi) 4-hydroxytestosterone (4,17[beta]-dihydroxy- androst-4-en-3-one), SB1585 Enrolled - 62 - LRB100 11277 SMS 21625 b (xxvii) 4-hydroxy-19-nortestosterone (4,17[beta]- dihydroxy-estr-4-en-3-one), (xxviii) mestanolone (17[alpha]-methyl-17[beta]- hydroxy-5-androstan-3-one), (xxix) mesterolone (1amethyl-17[beta]-hydroxy- [5a]-androstan-3-one), (xxx) methandienone (17[alpha]-methyl-17[beta]- hydroxyandrost-1,4-dien-3-one), (xxxi) methandriol (17[alpha]-methyl-3[beta],17[beta]- dihydroxyandrost-5-ene), (xxxii) methenolone (1-methyl-17[beta]-hydroxy- 5[alpha]-androst-1-en-3-one), (xxxiii) 17[alpha]-methyl-3[beta], 17[beta]- dihydroxy-5a-androstane), (xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy -5a-androstane), (xxxv) 17[alpha]-methyl-3[beta],17[beta]- dihydroxyandrost-4-ene), (xxxvi) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]- methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one), (xxxvii) methyldienolone (17[alpha]-methyl-17[beta]- hydroxyestra-4,9(10)-dien-3-one), (xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]- hydroxyestra-4,9-11-trien-3-one), (xxxix) methyltestosterone (17[alpha]-methyl-17[beta]- hydroxyandrost-4-en-3-one), SB1585 Enrolled - 63 - LRB100 11277 SMS 21625 b (xl) mibolerone (7[alpha],17a-dimethyl-17[beta]- hydroxyestr-4-en-3-one), (xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone (17b[beta]-hydroxy-17[alpha]-methyl-5[alpha]- androst-1-en-3-one)(a.k.a.
'17-[alpha]-methyl- 1-testosterone'), (xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one), (xliii) 19-nor-4-androstenediol (3[beta], 17[beta]- dihydroxyestr-4-ene), (xliv) 19-nor-4-androstenediol (3[alpha], 17[beta]- dihydroxyestr-4-ene), (xlv) 19-nor-5-androstenediol (3[beta], 17[beta]- dihydroxyestr-5-ene), (xlvi) 19-nor-5-androstenediol (3[alpha], 17[beta]- dihydroxyestr-5-ene), (xlvii) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione), (xlviii) 19-nor-4-androstenedione (estr-4- en-3,17-dione), (xlix) 19-nor-5-androstenedione (estr-5- en-3,17-dione), (l) norbolethone (13[beta], 17a-diethyl-17[beta]- hydroxygon-4-en-3-one), (li) norclostebol (4-chloro-17[beta]- hydroxyestr-4-en-3-one), (lii) norethandrolone (17[alpha]-ethyl-17[beta]- SB1585 Engrossed - 64 - LRB100 11277 SMS 21625 b hydroxyestr-4-en-3-one), (liii) normethandrolone (17[alpha]-methyl-17[beta]- hydroxyestr-4-en-3-one), (liv) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy- 2-oxa-5[alpha]-androstan-3-one), (lv) oxymesterone (17[alpha]-methyl-4,17[beta]- dihydroxyandrost-4-en-3-one), (lvi) oxymetholone (17[alpha]-methyl-2-hydroxymethylene- 17[beta]-hydroxy-(5[alpha]-androstan-3-one), (lvii) stanozolol (17[alpha]-methyl-17[beta]-hydroxy- (5[alpha]-androst-2-eno[3,2-c]-pyrazole), (lviii) stenbolone (17[beta]-hydroxy-2-methyl- (5[alpha]-androst-1-en-3-one), (lix) testolactone (13-hydroxy-3-oxo-13,17- secoandrosta-1,4-dien-17-oic acid lactone), (lx) testosterone (17[beta]-hydroxyandrost- 4-en-3-one), (lxi) tetrahydrogestrinone (13[beta], 17[alpha]- diethyl-17[beta]-hydroxygon- 4,9,11-trien-3-one), (lxii) trenbolone (17[beta]-hydroxyestr-4,9, 11-trien-3-one).
'17-[alpha]-methyl- 1-testosterone'), (xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one), (xliii) 19-nor-4-androstenediol (3[beta], 17[beta]- dihydroxyestr-4-ene), (xliv) 19-nor-4-androstenediol (3[alpha], 17[beta]- dihydroxyestr-4-ene), (xlv) 19-nor-5-androstenediol (3[beta], 17[beta]- dihydroxyestr-5-ene), (xlvi) 19-nor-5-androstenediol (3[alpha], 17[beta]- dihydroxyestr-5-ene), (xlvii) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione), (xlviii) 19-nor-4-androstenedione (estr-4- en-3,17-dione), (xlix) 19-nor-5-androstenedione (estr-5- en-3,17-dione), (l) norbolethone (13[beta], 17a-diethyl-17[beta]- hydroxygon-4-en-3-one), (li) norclostebol (4-chloro-17[beta]- hydroxyestr-4-en-3-one), (lii) norethandrolone (17[alpha]-ethyl-17[beta]- SB1585 Enrolled - 64 - LRB100 11277 SMS 21625 b hydroxyestr-4-en-3-one), (liii) normethandrolone (17[alpha]-methyl-17[beta]- hydroxyestr-4-en-3-one), (liv) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy- 2-oxa-5[alpha]-androstan-3-one), (lv) oxymesterone (17[alpha]-methyl-4,17[beta]- dihydroxyandrost-4-en-3-one), (lvi) oxymetholone (17[alpha]-methyl-2-hydroxymethylene- 17[beta]-hydroxy-(5[alpha]-androstan-3-one), (lvii) stanozolol (17[alpha]-methyl-17[beta]-hydroxy- (5[alpha]-androst-2-eno[3,2-c]-pyrazole), (lviii) stenbolone (17[beta]-hydroxy-2-methyl- (5[alpha]-androst-1-en-3-one), (lix) testolactone (13-hydroxy-3-oxo-13,17- secoandrosta-1,4-dien-17-oic acid lactone), (lx) testosterone (17[beta]-hydroxyandrost- 4-en-3-one), (lxi) tetrahydrogestrinone (13[beta], 17[alpha]- diethyl-17[beta]-hydroxygon- 4,9,11-trien-3-one), (lxii) trenbolone (17[beta]-hydroxyestr-4,9, 11-trien-3-one).
Any person who is otherwise lawfully in possession of an anabolic steroid, or who otherwise lawfully manufactures, distributes, dispenses, delivers, or possesses with intent to SB1585 Engrossed - 65 - LRB100 11277 SMS 21625 b deliver an anabolic steroid, which anabolic steroid is expressly intended for and lawfully allowed to be administered through implants to livestock or other nonhuman species, and which is approved by the Secretary of Health and Human Services for such administration, and which the person intends to administer or have administered through such implants, shall not be considered to be in unauthorized possession or to unlawfully manufacture, distribute, dispense, deliver, or possess with intent to deliver such anabolic steroid for purposes of this Act.
Any person who is otherwise lawfully in possession of an anabolic steroid, or who otherwise lawfully manufactures, distributes, dispenses, delivers, or possesses with intent to SB1585 Enrolled - 65 - LRB100 11277 SMS 21625 b deliver an anabolic steroid, which anabolic steroid is expressly intended for and lawfully allowed to be administered through implants to livestock or other nonhuman species, and which is approved by the Secretary of Health and Human Services for such administration, and which the person intends to administer or have administered through such implants, shall not be considered to be in unauthorized possession or to unlawfully manufacture, distribute, dispense, deliver, or possess with intent to deliver such anabolic steroid for purposes of this Act.
"Compounding" includes the preparation of drugs SB1585 Engrossed - 66 - LRB100 11277 SMS 21625 b or devices in anticipation of receiving prescription drug orders based on routine, regularly observed dispensing patterns.
"Compounding" includes the preparation of drugs SB1585 Enrolled - 66 - LRB100 11277 SMS 21625 b or devices in anticipation of receiving prescription drug orders based on routine, regularly observed dispensing patterns.
(2) which has a stimulant, depressant, or hallucinogenic effect on the central nervous system that is SB1585 Engrossed - 67 - LRB100 11277 SMS 21625 b substantially similar to or greater than the stimulant, depressant, or hallucinogenic effect on the central nervous system of a controlled substance in Schedule I or II;
(2) which has a stimulant, depressant, or hallucinogenic effect on the central nervous system that is SB1585 Enrolled - 67 - LRB100 11277 SMS 21625 b substantially similar to or greater than the stimulant, depressant, or hallucinogenic effect on the central nervous system of a controlled substance in Schedule I or II;
SB1585 Engrossed - 68 - LRB100 11277 SMS 21625 b (k) "Department of Corrections" means the Department of Corrections of the State of Illinois or its successor agency.
SB1585 Enrolled - 68 - LRB100 11277 SMS 21625 b (k) "Department of Corrections" means the Department of Corrections of the State of Illinois or its successor agency.
SB1585 Engrossed - 69 - LRB100 11277 SMS 21625 b (t) "Drug" means (1) substances recognized as drugs in the official United States Pharmacopoeia, Official Homeopathic Pharmacopoeia of the United States, or official National Formulary, or any supplement to any of them;
SB1585 Enrolled - 69 - LRB100 11277 SMS 21625 b (t) "Drug" means (1) substances recognized as drugs in the official United States Pharmacopoeia, Official Homeopathic Pharmacopoeia of the United States, or official National Formulary, or any supplement to any of them;
SB1585 Engrossed - 70 - LRB100 11277 SMS 21625 b (u) "Good faith" means the prescribing or dispensing of a controlled substance by a practitioner in the regular course of professional treatment to or for any person who is under his or her treatment for a pathology or condition other than that individual's physical or psychological dependence upon or addiction to a controlled substance, except as provided herein:
SB1585 Enrolled - 70 - LRB100 11277 SMS 21625 b (u) "Good faith" means the prescribing or dispensing of a controlled substance by a practitioner in the regular course of professional treatment to or for any person who is under his or her treatment for a pathology or condition other than that individual's physical or psychological dependence upon or addiction to a controlled substance, except as provided herein:
SB1585 Engrossed - 71 - LRB100 11277 SMS 21625 b (u-1) "Home infusion services" means services provided by a pharmacy in compounding solutions for direct administration to a patient in a private residence, long-term care facility, or hospice setting by means of parenteral, intravenous, intramuscular, subcutaneous, or intraspinal infusion.
SB1585 Enrolled - 71 - LRB100 11277 SMS 21625 b (u-1) "Home infusion services" means services provided by a pharmacy in compounding solutions for direct administration to a patient in a private residence, long-term care facility, or hospice setting by means of parenteral, intravenous, intramuscular, subcutaneous, or intraspinal infusion.
(y) "Look-alike substance" means a substance, other than a controlled substance which (1) by overall dosage unit SB1585 Engrossed - 72 - LRB100 11277 SMS 21625 b appearance, including shape, color, size, markings or lack thereof, taste, consistency, or any other identifying physical characteristic of the substance, would lead a reasonable person to believe that the substance is a controlled substance, or (2) is expressly or impliedly represented to be a controlled substance or is distributed under circumstances which would lead a reasonable person to believe that the substance is a controlled substance.
(y) "Look-alike substance" means a substance, other than a controlled substance which (1) by overall dosage unit SB1585 Enrolled - 72 - LRB100 11277 SMS 21625 b appearance, including shape, color, size, markings or lack thereof, taste, consistency, or any other identifying physical characteristic of the substance, would lead a reasonable person to believe that the substance is a controlled substance, or (2) is expressly or impliedly represented to be a controlled substance or is distributed under circumstances which would lead a reasonable person to believe that the substance is a controlled substance.
SB1585 Engrossed - 73 - LRB100 11277 SMS 21625 b Clause (1) of this subsection (y) shall not apply to a noncontrolled substance in its finished dosage form that was initially introduced into commerce prior to the initial introduction into commerce of a controlled substance in its finished dosage form which it may substantially resemble.
SB1585 Enrolled - 73 - LRB100 11277 SMS 21625 b Clause (1) of this subsection (y) shall not apply to a noncontrolled substance in its finished dosage form that was initially introduced into commerce prior to the initial introduction into commerce of a controlled substance in its finished dosage form which it may substantially resemble.
(z) "Manufacture" means the production, preparation, propagation, compounding, conversion or processing of a controlled substance other than methamphetamine, either directly or indirectly, by extraction from substances of natural origin, or independently by means of chemical SB1585 Engrossed - 74 - LRB100 11277 SMS 21625 b synthesis, or by a combination of extraction and chemical synthesis, and includes any packaging or repackaging of the substance or labeling of its container, except that this term does not include:
(z) "Manufacture" means the production, preparation, propagation, compounding, conversion or processing of a controlled substance other than methamphetamine, either directly or indirectly, by extraction from substances of natural origin, or independently by means of chemical SB1585 Enrolled - 74 - LRB100 11277 SMS 21625 b synthesis, or by a combination of extraction and chemical synthesis, and includes any packaging or repackaging of the substance or labeling of its container, except that this term does not include:
(z-10) "Mid-level practitioner" means (i) a physician assistant who has been delegated authority to prescribe through a written delegation of authority by a physician licensed to practice medicine in all of its branches, in accordance with Section 7.5 of the Physician Assistant Practice Act of 1987, (ii) an advanced practice nurse who has been delegated authority to prescribe through a written delegation of authority by a physician licensed to practice medicine in all SB1585 Engrossed - 75 - LRB100 11277 SMS 21625 b of its branches or by a podiatric physician, in accordance with Section 65-40 of the Nurse Practice Act, (iii) an advanced practice nurse certified as a nurse practitioner, nurse midwife, or clinical nurse specialist who has been granted authority to prescribe by a hospital affiliate in accordance with Section 65-45 of the Nurse Practice Act, (iv) an animal euthanasia agency, or (v) a prescribing psychologist.
(z-10) "Mid-level practitioner" means (i) a physician assistant who has been delegated authority to prescribe through a written delegation of authority by a physician licensed to practice medicine in all of its branches, in accordance with Section 7.5 of the Physician Assistant Practice Act of 1987, (ii) an advanced practice nurse who has been delegated authority to prescribe through a written delegation of authority by a physician licensed to practice medicine in all SB1585 Enrolled - 75 - LRB100 11277 SMS 21625 b of its branches or by a podiatric physician, in accordance with Section 65-40 of the Nurse Practice Act, (iii) an advanced practice nurse certified as a nurse practitioner, nurse midwife, or clinical nurse specialist who has been granted authority to prescribe by a hospital affiliate in accordance with Section 65-45 of the Nurse Practice Act, (iv) an animal euthanasia agency, or (v) a prescribing psychologist.
(5) cocaine, its salts, optical and geometric isomers, SB1585 Engrossed - 76 - LRB100 11277 SMS 21625 b and salts of isomers;
(5) cocaine, its salts, optical and geometric isomers, SB1585 Enrolled - 76 - LRB100 11277 SMS 21625 b and salts of isomers;
SB1585 Engrossed - 77 - LRB100 11277 SMS 21625 b (hh) "Pharmacist" means any person who holds a license or certificate of registration as a registered pharmacist, a local registered pharmacist or a registered assistant pharmacist under the Pharmacy Practice Act.
SB1585 Enrolled - 77 - LRB100 11277 SMS 21625 b (hh) "Pharmacist" means any person who holds a license or certificate of registration as a registered pharmacist, a local registered pharmacist or a registered assistant pharmacist under the Pharmacy Practice Act.
(ll) "Pre-printed prescription" means a written SB1585 Engrossed - 78 - LRB100 11277 SMS 21625 b prescription upon which the designated drug has been indicated prior to the time of issuance;
(ll) "Pre-printed prescription" means a written SB1585 Enrolled - 78 - LRB100 11277 SMS 21625 b prescription upon which the designated drug has been indicated prior to the time of issuance;
(nn) "Prescription" means a written, facsimile, or oral order, or an electronic order that complies with applicable SB1585 Engrossed - 79 - LRB100 11277 SMS 21625 b federal requirements, of a physician licensed to practice medicine in all its branches, dentist, podiatric physician or veterinarian for any controlled substance, of an optometrist in accordance with Section 15.1 of the Illinois Optometric Practice Act of 1987, of a prescribing psychologist licensed under Section 4.2 of the Clinical Psychologist Licensing Act with prescriptive authority delegated under Section 4.3 of the Clinical Psychologist Licensing Act, of a physician assistant for a controlled substance in accordance with Section 303.05, a written delegation, and a written collaborative supervision agreement required under Section 7.5 of the Physician Assistant Practice Act of 1987, of an advanced practice nurse with prescriptive authority delegated under Section 65-40 of the Nurse Practice Act who issues a prescription for a controlled substance in accordance with Section 303.05, a written delegation, and a written collaborative agreement under Section 65-35 of the Nurse Practice Act, or of an advanced practice nurse certified as a nurse practitioner, nurse midwife, or clinical nurse specialist who has been granted authority to prescribe by a hospital affiliate in accordance with Section 65-45 of the Nurse Practice Act and in accordance with Section 303.05 when required by law.
(nn) "Prescription" means a written, facsimile, or oral order, or an electronic order that complies with applicable SB1585 Enrolled - 79 - LRB100 11277 SMS 21625 b federal requirements, of a physician licensed to practice medicine in all its branches, dentist, podiatric physician or veterinarian for any controlled substance, of an optometrist in accordance with Section 15.1 of the Illinois Optometric Practice Act of 1987, of a prescribing psychologist licensed under Section 4.2 of the Clinical Psychologist Licensing Act with prescriptive authority delegated under Section 4.3 of the Clinical Psychologist Licensing Act, of a physician assistant for a controlled substance in accordance with Section 303.05, a written delegation, and a written collaborative supervision agreement required under Section 7.5 of the Physician Assistant Practice Act of 1987, of an advanced practice nurse with prescriptive authority delegated under Section 65-40 of the Nurse Practice Act who issues a prescription for a controlled substance in accordance with Section 303.05, a written delegation, and a written collaborative agreement under Section 65-35 of the Nurse Practice Act, or of an advanced practice nurse certified as a nurse practitioner, nurse midwife, or clinical nurse specialist who has been granted authority to prescribe by a hospital affiliate in accordance with Section 65-45 of the Nurse Practice Act and in accordance with Section 303.05 when required by law.
(nn-10) "Prescription Monitoring Program" (PMP) means the SB1585 Engrossed - 80 - LRB100 11277 SMS 21625 b entity that collects, tracks, and stores reported data on controlled substances and select drugs pursuant to Section 316.
(nn-10) "Prescription Monitoring Program" (PMP) means the SB1585 Enrolled - 80 - LRB100 11277 SMS 21625 b entity that collects, tracks, and stores reported data on controlled substances and select drugs pursuant to Section 316.
(ss) "Ultimate user" means a person who lawfully possesses SB1585 Engrossed - 81 - LRB100 11277 SMS 21625 b a controlled substance for his or her own use or for the use of a member of his or her household or for administering to an animal owned by him or her or by a member of his or her household.
(ss) "Ultimate user" means a person who lawfully possesses SB1585 Enrolled - 81 - LRB100 11277 SMS 21625 b a controlled substance for his or her own use or for the use of a member of his or her household or for administering to an animal owned by him or her or by a member of his or her household.
and the physician assistant has SB1585 Engrossed - 82 - LRB100 11277 SMS 21625 b completed the appropriate application forms and has paid the required fees as set by rule;
and the physician assistant has SB1585 Enrolled - 82 - LRB100 11277 SMS 21625 b completed the appropriate application forms and has paid the required fees as set by rule;
SB1585 Engrossed - 83 - LRB100 11277 SMS 21625 b (iv) the physician assistant must discuss the condition of any patients for whom a controlled substance is prescribed monthly with the delegating physician;
SB1585 Enrolled - 83 - LRB100 11277 SMS 21625 b (iv) the physician assistant must discuss the condition of any patients for whom a controlled substance is prescribed monthly with the delegating physician;
The advanced SB1585 Engrossed - 84 - LRB100 11277 SMS 21625 b practice nurse has completed the appropriate application forms and has paid the required fees as set by rule;
The advanced SB1585 Enrolled - 84 - LRB100 11277 SMS 21625 b practice nurse has completed the appropriate application forms and has paid the required fees as set by rule;
(iii) all prescriptions must be limited to no more than a 30-day supply, with any continuation authorized only after prior approval of the SB1585 Engrossed - 85 - LRB100 11277 SMS 21625 b collaborating physician or podiatric physician;
(iii) all prescriptions must be limited to no more than a 30-day supply, with any continuation authorized only after prior approval of the SB1585 Enrolled - 85 - LRB100 11277 SMS 21625 b collaborating physician or podiatric physician;
(2.5) with respect to advanced practice nurses certified as nurse practitioners, nurse midwives, or clinical nurse specialists practicing in a hospital affiliate, (A) the advanced practice nurse certified as a nurse practitioner, nurse midwife, or clinical nurse specialist has been granted authority to prescribe any SB1585 Engrossed - 86 - LRB100 11277 SMS 21625 b Schedule II through V controlled substances by the hospital affiliate upon the recommendation of the appropriate physician committee of the hospital affiliate in accordance with Section 65-45 of the Nurse Practice Act, has completed the appropriate application forms, and has paid the required fees as set by rule;
(2.5) with respect to advanced practice nurses certified as nurse practitioners, nurse midwives, or clinical nurse specialists practicing in a hospital affiliate, (A) the advanced practice nurse certified as a nurse practitioner, nurse midwife, or clinical nurse specialist has been granted authority to prescribe any SB1585 Enrolled - 86 - LRB100 11277 SMS 21625 b Schedule II through V controlled substances by the hospital affiliate upon the recommendation of the appropriate physician committee of the hospital affiliate in accordance with Section 65-45 of the Nurse Practice Act, has completed the appropriate application forms, and has paid the required fees as set by rule;
SB1585 Engrossed - 87 - LRB100 11277 SMS 21625 b (ii) any grant of authority must be controlled substances limited to the practice of the advanced practice nurse;
SB1585 Enrolled - 87 - LRB100 11277 SMS 21625 b (ii) any grant of authority must be controlled substances limited to the practice of the advanced practice nurse;
(b) The mid-level practitioner shall only be licensed to SB1585 Engrossed - 88 - LRB100 11277 SMS 21625 b prescribe those schedules of controlled substances for which a licensed physician or licensed podiatric physician has delegated prescriptive authority, except that an animal euthanasia agency does not have any prescriptive authority.
(b) The mid-level practitioner shall only be licensed to SB1585 Enrolled - 88 - LRB100 11277 SMS 21625 b prescribe those schedules of controlled substances for which a licensed physician or licensed podiatric physician has delegated prescriptive authority, except that an animal euthanasia agency does not have any prescriptive authority.
SB1585 Engrossed - 89 - LRB100 11277 SMS 21625 b (Source:
SB1585 Enrolled - 89 - LRB100 11277 SMS 21625 b (Source:
⬇ Download PDF
View plain text versions (3)

Action History

  1. Public Act . . . . . . . . . 100-0453

  2. Effective Date August 25, 2017

  3. Governor Approved

  4. Sent to the Governor

  5. Passed Both Houses

  6. Third Reading - Short Debate - Passed 116-000-000

  7. Final Action Deadline Extended-9(b) May 31, 2017

  8. Placed on Calendar Order of 3rd Reading - Short Debate

  9. Second Reading - Short Debate

  10. Added Alternate Co-Sponsor Rep. Joe Sosnowski

  11. Added Alternate Co-Sponsor Rep. Tom Demmer

  12. Placed on Calendar 2nd Reading - Short Debate

  13. Do Pass / Short Debate Health Care Licenses Committee; 016-000-000

  14. Added Alternate Co-Sponsor Rep. Frances Ann Hurley

  15. Added Alternate Co-Sponsor Rep. Kelly M. Burke

  16. Added Alternate Co-Sponsor Rep. Mary E. Flowers

  17. Added Alternate Co-Sponsor Rep. David S. Olsen

  18. Added Alternate Co-Sponsor Rep. La Shawn K. Ford

  19. Added Alternate Co-Sponsor Rep. Anna Moeller

  20. Added Alternate Co-Sponsor Rep. Barbara Wheeler

  21. Added Alternate Co-Sponsor Rep. Emanuel Chris Welch

  22. Added Alternate Co-Sponsor Rep. Luis Arroyo

  23. Added Alternate Co-Sponsor Rep. Daniel J. Burke

  24. Added Alternate Co-Sponsor Rep. Nick Sauer

  25. Assigned to Health Care Licenses Committee

  26. Added Alternate Co-Sponsor Rep. Steven A. Andersson

  27. Added Alternate Chief Co-Sponsor Rep. Michael J. Zalewski

  28. Added Alternate Chief Co-Sponsor Rep. Brandon W. Phelps

  29. Added Alternate Chief Co-Sponsor Rep. Randy E. Frese

  30. Added Alternate Chief Co-Sponsor Rep. Tony McCombie

  31. Added Alternate Co-Sponsor Rep. Michael Halpin

  32. Added Alternate Co-Sponsor Rep. Jaime M. Andrade, Jr.

  33. Referred to Rules Committee

  34. First Reading

  35. Chief House Sponsor Rep. Cynthia Soto

  36. Arrived in House

  37. Third Reading - Passed; 057-000-000

  38. Added as Co-Sponsor Sen. Neil Anderson

  39. Placed on Calendar Order of 3rd Reading April 27, 2017

  40. Senate Floor Amendment No. 2 Adopted; Martinez

  41. Senate Floor Amendment No. 1 Adopted; Martinez

  42. Recalled to Second Reading

  43. Senate Floor Amendment No. 2 Recommend Do Adopt Licensed Activities and Pensions; 009-000-000

  44. Senate Floor Amendment No. 1 Recommend Do Adopt Licensed Activities and Pensions; 009-000-000

  45. Placed on Calendar Order of 3rd Reading April 27, 2017

  46. Second Reading

  47. Senate Floor Amendment No. 2 Assignments Refers to Licensed Activities and Pensions

  48. Senate Floor Amendment No. 2 Referred to Assignments

  49. Senate Floor Amendment No. 2 Filed with Secretary by Sen. Iris Y. Martinez

  50. Senate Floor Amendment No. 1 Postponed - Licensed Activities and Pensions

  51. Senate Floor Amendment No. 1 Assignments Refers to Licensed Activities and Pensions

  52. Senate Floor Amendment No. 1 Referred to Assignments

  53. Senate Floor Amendment No. 1 Filed with Secretary by Sen. Iris Y. Martinez

  54. Added as Co-Sponsor Sen. Tom Rooney

  55. Placed on Calendar Order of 2nd Reading March 28, 2017

  56. Do Pass Licensed Activities and Pensions; 011-000-000

  57. Added as Co-Sponsor Sen. Antonio Muñoz

  58. Added as Co-Sponsor Sen. Chapin Rose

  59. Postponed - Licensed Activities and Pensions

  60. Assigned to Licensed Activities and Pensions

  61. Added as Chief Co-Sponsor Sen. Michael Connelly

  62. Added as Chief Co-Sponsor Sen. Pamela J. Althoff

  63. Referred to Assignments

  64. First Reading

  65. Filed with Secretary by Sen. Iris Y. Martinez

Sponsors

  • Iris Y. Martinez · Cosponsor
  • Jr. Jaime M. Andrade · Cosponsor
  • Michael W. Halpin · Cosponsor
  • Steven A. Andersson · Cosponsor
  • Nick Sauer · Cosponsor
  • Daniel J. Burke · Cosponsor
  • Luis Arroyo · Cosponsor
  • Emanuel Chris Welch · Cosponsor
  • Barbara Wheeler · Cosponsor
  • Anna Moeller · Cosponsor
  • La Shawn K. Ford · Cosponsor
  • David S. Olsen · Cosponsor
  • Mary E. Flowers · Cosponsor
  • Kelly M. Burke · Cosponsor
  • Frances Ann Hurley · Cosponsor
  • Tom Demmer · Cosponsor
  • Joe C. Sosnowski · Cosponsor

Sponsorship breakdown

Export CSV (upgrade) →

0 sponsors · 17 co-sponsors · 166 not signed on

Sponsors (0)

None.

Co-sponsors (17)

Not signed on (166)

166 members have not signed on to this bill.

Show all 166 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Votes

Third Reading

Passed 116 Yea · 0 Nay · 2 Other
Party YeaNayPresentNot Voting
Unaffiliated 72002
Republican 12000
Democrat 32000
Total 116002
% of votes cast 98%0%0%2%
How each member voted (118)
Member Party Vote
Batinick — Not Voting
Beiser — Yea
Bellock — Yea
Bourne — Yea
Breen — Yea
Butler — Yea
McAsey — Not Voting
McAuliffe — Yea
Durkin — Yea
Flowers — Yea
Frese — Yea
Cavaletto — Yea
Conroy — Yea
Conyears-Ervin — Yea
Lang — Yea
Long — Yea
Phillips — Yea
Sente — Yea
Stewart — Yea
Harris, David — Yea
Stratton — Yea
Sauer — Yea
Harris, Gregory — Yea
Bennett — Yea
Hernandez — Yea
Brady — Yea
Burke, Daniel — Yea
Burke, Kelly — Yea
Jones — Yea
Greenwood — Yea
Hays — Yea
Hurley — Yea
Ives — Yea
Jesiel — Yea
Jimenez — Yea
McDermed — Yea
McSweeney — Yea
Davis — Yea
Mitchell, Bill — Yea
Nekritz — Yea
Wheeler, Barbara — Yea
Mitchell, Christian — Yea
Wheeler, Keith — Yea
Olsen — Yea
Williams — Yea
Tabares — Yea
Thapedi — Yea
Turner — Yea
Unes — Yea
Wallace — Yea
Wehrli — Yea
Welter — Yea
Winger — Yea
Costello — Yea
Currie — Yea
D'Amico — Yea
Demmer — Yea
Drury — Yea
Fortner — Yea
Yingling — Yea
Parkhurst — Yea
Phelps — Yea
Pritchard — Yea
Reis — Yea
Riley — Yea
Skillicorn — Yea
Sommer — Yea
Soto — Yea
Willis — Yea
Zalewski — Yea
Madigan — Yea
Andersson — Yea
Arroyo — Yea
Chapa LaVia — Yea
Anna Moeller Democrat Yea
Anthony DeLuca Democrat Yea
Camille Y. Lilly Democrat Yea
Carol Ammons Democrat Yea
Elgie R. Sims, Jr. Democrat Yea
Emanuel "Chris" Welch Democrat Yea
Fred Crespo Democrat Yea
Jaime M. Andrade, Jr. Democrat Yea
Jay Hoffman Democrat Yea
Jehan Gordon-Booth Democrat Yea
Julie A. Morrison Democrat Yea
Justin Slaughter Democrat Yea
Katie Stuart Democrat Yea
Kelly M. Cassidy Democrat Yea
La Shawn K. Ford Democrat Yea
Laura Fine Democrat Yea
Lawrence "Larry" Walsh, Jr. Democrat Yea
Marcus C. Evans, Jr. Democrat Yea
Martin J. Moylan Democrat Yea
Michael W. Halpin Democrat Yea
Michelle Mussman Democrat Yea
Natalie A. Manley Democrat Yea
Rita Mayfield Democrat Yea
Robert "Bob" Rita Democrat Yea
Robert F. Martwick Democrat Yea
Robyn Gabel Democrat Yea
Sara Feigenholtz Democrat Yea
Sonya M. Harper Democrat Yea
Stephanie A. Kifowit Democrat Yea
Sue Scherer Democrat Yea
Theresa Mah Democrat Yea
Will Guzzardi Democrat Yea
Brad Halbrook Republican Yea
Charles Meier Republican Yea
Christopher "C.D." Davidsmeyer Republican Yea
Dan Swanson Republican Yea
Dave Severin Republican Yea
Joe C. Sosnowski Republican Yea
John M. Cabello Republican Yea
Norine K. Hammond Republican Yea
Ryan Spain Republican Yea
Steven Reick Republican Yea
Terri Bryant Republican Yea
Tony M. McCombie Republican Yea

Official roll call →

Third Reading

Passed 57 Yea · 0 Nay · 2 Other
Party YeaNayPresentNot Voting
Unaffiliated 36001
Democrat 13001
Republican 8000
Total 57002
% of votes cast 97%0%0%3%
How each member voted (59)
Member Party Vote
Barickman — Yea
Bertino-Tarrant — Yea
Biss — Yea
Bivins — Yea
Landek — Yea
Link — Yea
Rooney — Yea
Manar — Yea
McCann — Yea
McCarter — Yea
Harris — Yea
Bennett — Yea
McGuire — Yea
McConnaughay — Yea
Mulroe — Yea
Muñoz — Yea
Oberweis — Yea
Brady — Yea
Radogno — Yea
Silverstein — Yea
Cullerton — Yea
Steans — Yea
Cullerton, T. — Yea
Trotter — Yea
Bush — Yea
Clayborne — Yea
Connelly — Yea
Haine — Not Voting
Hutchinson — Yea
Nybo — Yea
Raoul — Yea
Righter — Yea
Sandoval — Yea
Schimpf — Yea
Althoff — Yea
Martinez — Yea
Van Pelt — Yea
Bill Cunningham Democrat Yea
Cristina Castro Democrat Yea
David Koehler Democrat Yea
Don Harmon Democrat Yea
Emil Jones, III Democrat Yea
Julie A. Morrison Democrat Yea
Kimberly A. Lightford Democrat Yea
Lakesia Collins Democrat Yea
Laura M. Murphy Democrat Yea
Linda Holmes Democrat Yea
Mattie Hunter Democrat Yea
Michael E. Hastings Democrat Not Voting
Omar Aquino Democrat Yea
Steve Stadelman Democrat Yea
Chapin Rose Republican Yea
Dale Fowler Republican Yea
Dan McConchie Republican Yea
Dave Syverson Republican Yea
Jil Tracy Republican Yea
Neil Anderson Republican Yea
Sue Rezin Republican Yea
Travis Weaver Republican Yea

Official roll call →

Subjects

healthcare labor
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does SB 1585 do?
Amends the Regulatory Sunset Act. Extends the repeal date of the Physician Assistant Practice Act of 1987 from January 1, 2018 to January 1, 2028. Amends the Physician Assistant Practice Act of 1987. Reorganizes the Act by adding titles and renumbering provisions. Replaces references to "supervising physicians" with references to "collaborating physicians" throughout the Act. Replaces references to "supervision agreement" with references to "collaborative agreement" throughout the Act. Adds provisions concerning continuing education. In provisions concerning grounds for disciplinary action, provides that the Department of Financial and Professional Regulation may refuse to issue or renew a physician assistant license or discipline a licensee for willfully or negligently violating a patient's confidentiality, except as required by law, or failing to provide copies of medical records as required by law. Amends various Acts to conform references and terminology. Makes other changes. Effective immediately.
Who sponsors SB 1585?
SB 1585 is sponsored by Iris Y. Martinez, Jaime M. Andrade, Jr. (Democrat), Michael W. Halpin (Democrat), Steven A. Andersson, Nick Sauer, Daniel J. Burke, Luis Arroyo, Emanuel Chris Welch, Barbara Wheeler, Anna Moeller (Democrat), La Shawn K. Ford, David S. Olsen, Mary E. Flowers, Kelly M. Burke, Frances Ann Hurley, Tom Demmer, and Joe C. Sosnowski (Republican).
What is the current status of SB 1585?
This bill has been enacted into law. Introduced February 09, 2017. Enacted.
Where can I track SB 1585?
Track SB 1585 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on SB 1585

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of SB 1585

Last checked for changes 3 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →